Citations 1
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia
Parrondo, Ricardo , Dutta, Navnita , LaPlant, Betsy, Elliott, Jamie, Fernandez, Andre, Zimmerman, Ashley, Cicco, Gina, Han, Bing , Heslop, Keisha, Chapin, Dustin, Sher, Taimur , Rasheed, Ahsan , Das, Saurav , Chanan‐Khan, Asher , Paulus, Aneel , Parrondo, Ricardo D , LaPlant, Betsy R, Das, Saurav , Chanan-Khan, Asher , Ailawadhi, Sikander , Paulus, Aneel , Cicco, Gina, Roy, Vivek , Ailawadhi, Sikander
British Journal of Haematology | January 30, 2024 | Volume: 204 | Issue: 5 | Pages: 1825-1829
SummaryThis phase II study evaluated time‐limited (24 cycles) treatment with ibrutinib and ixazomib in newly diagnosed (NDWM; n = 9) and relapsed/refractory (RRWM; n = 12) Waldenström macroglobulinaemia (WM). The overall response rate (ORR) was 76.2% (n = 16) in 21 evaluable patients with no patient achieving a complete response (CR). The median duration of treatment was 15.6 months, and after a median follow‐up time of 25.7 months, the median progression‐free survival (PFS) was 22.9 months. While the primary end‐point was not met (CR rate at any time) and 28.5% discontinued treatment due to toxicity, ibrutinib plus ixazomib led to a clinically meaningful ORR and PFS. Combined Bruton's tyrosine kinase (BTK) and proteasome inhibition merits further evaluation in WM.